Retatrutide

Mechanism of Action

Retatrutide is a synthetic peptide agonist of multiple hormone receptors including GLP-1, GIP, and glucagon receptors. By activating these receptors, it modulates metabolic pathways to reduce appetite, enhance insulin sensitivity, promote energy expenditure, and regulate glucose homeostasis, overall contributing to weight loss and improved metabolic function.

Reported Research Benefits

• Primarily studied in experimental models for metabolic disorders and obesity, Retatrutide is used in research investigating weight-regulation mechanisms, glucose metabolism, and potential therapeutic applications in treating type 2 diabetes and obesity.

Dosing Protocol & Reconstitution

Research Notes

Clinical trials demonstrate that Retatrutide can significantly reduce body weight and improve glycemic control with an extended half-life allowing weekly administration. It is under investigation for long-term safety and efficacy in metabolic diseases.

Research Summary

Retatrutide (LY3437943) is a triple incretin agonist targeting GLP-1, GIP, and glucagon receptors — the first in its class. Phase II trials showed mean weight loss of 24.2% at 48 weeks, outperforming all currently approved obesity medications. Glucagon co-agonism provides enhanced energy expenditure and hepatic fat reduction beyond dual GLP-1/GIP agonists.

Side Effects & Safety

GI side effects (nausea, vomiting, diarrhea) are common, particularly during dose escalation, consistent with GLP-1 agonist class effects. Decreased appetite, constipation, and injection site reactions also reported. Thyroid C-cell tumor risk (rodent-only findings) carries class-wide warning. Contraindicated in personal/family history of MEN-2 or medullary thyroid carcinoma.

Stability & Storage

Refer to research notes

Molecular Data

Primary literature: https://pubmed.ncbi.nlm.nih.gov/?term=retatrutide+GLP-1+GIP+glucagon+obesity